The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF).
 
Prithviraj Bose
Honoraria - AbbVie; Blueprint Medicines; Bristol-Myers Squibb; Cogent Biosciences; CTI; GlaxoSmithKline/Sierra Oncology; Incyte; Karyopharm Therapeutics; MorphoSys; Novartis; PharmaEssentia
Research Funding - Blueprint Medicines; Bristol-Myers Squibb; Cogent Biosciences; CTI; Disc Medicine; Incyte; Ionis Pharmaceuticals; Kartos Therapeutics; Morphosys; NS Pharma; Promedior; Telios
 
Sanjay Mohan
Research Funding - Incyte (Inst); Karyopharm Therapeutics (Inst); Taiho Pharmaceutical (Inst)
 
Stephen Oh
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; Cogent Biosciences; Constellation Pharmaceuticals; CTI BioPharma Corp; Geron; Incyte; Protagonist Therapeutics; Sierra Oncology
Research Funding - Actuate Therapeutics (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb/Celgene (Inst); Cogent Biosciences (Inst); Constellation Pharmaceuticals (Inst); CTI (Inst); Incyte (Inst); Ionis Pharmaceuticals (Inst); Kartos Therapeutics (Inst); Pharmaessentia (Inst); Sierra Oncology (Inst); Takeda (Inst)
 
Jason R. Gotlib
Honoraria - Abbvie; Blueprint Medicines; Cogent Biosciences; Deciphera; Imago Biosciences; Incyte; Kartos Therapeutics; Novartis; PharmaEssentia; Protagonist Therapeutics
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Cogent Biosciences; Deciphera; Imago Biosciences; Incyte; Kartos Therapeutics; Novartis; PharmaEssentia; Protagonist Therapeutics
Research Funding - Abbvie; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Cogent Biosciences; Deciphera; Imago Biosciences; Incyte; Kartos Therapeutics; Novartis; Protagonist Therapeutics
 
Ellen K. Ritchie
Consulting or Advisory Role - bristol myers squibb; Celgene; Incyte; Novartis; Pfizer
Speakers' Bureau - Celgene; Incyte
Research Funding - Astellas Pharma (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Taizo Shimomura
No Relationships to Disclose
 
Haris Ali
Leadership - Abbvie; Bristol-Myers Squibb; Incyte
Speakers' Bureau - Abbvie; Bristol-Myers Squibb; Incyte
 
Francoise Boyer
Honoraria - Novartis
Consulting or Advisory Role - Novartis
Travel, Accommodations, Expenses - Novartis
 
Paola Guglielmelli
Consulting or Advisory Role - AbbVie; Novartis Biociencias
Speakers' Bureau - AbbVie; GlaxoSmithKline; Novartis
 
Anthony Hunter
Consulting or Advisory Role - Sierra Oncology
 
Betty Lamothe
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Yi Cui
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Francis Seguy
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Amanda McBride
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Francesca Palandri
Honoraria - AOP Orphan Pharmaceuticals; Celgene; CTI; Novartis; Sierra Oncology
Consulting or Advisory Role - AOP Orphan Pharmaceuticals; Celgene; CTI; Novartis; Sierra Oncology
 
Masahiro Takeuchi
No Relationships to Disclose
 
Jean-Jacques Kiladjian
Consulting or Advisory Role - Abbvie; AOP Health; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Novartis